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Evaluating the Allergenic
Potential of Genetically
Modiﬁed Foods
The application of biotechnology to food
production offers great promise in increasing
crop production through development of
plants that have an increased yield through
resistance to changes of temperature and
drought and the expression of natural pesti-
cides, lessening the need for the application of
exogenous pesticides (Astwood et al. 1997;
Mann 1997). Plants may also be developed in
which toxin content is downregulated, immu-
nizing proteins are expressed, fat/protein ratio
is altered, palatability is increased, and appear-
ance is more appealing (Arntzen 1998). Crops
may be developed that naturally express vita-
mins or that are deﬁcient in speciﬁc allergens
known to cause problems upon ingestion by
individuals sensitive to the allergens within the
native plant (Friedrich 1999).
It is inevitable that application of this
technology has raised a number of fundamen-
tal concerns, including the consequences of
reporter genes, the spread of resistance genes
to surrounding plants, the use of suicide
genes to prohibit reuse of seed from engi-
neered plants, and finally, whether these
altered plants may be allergenic (Lehrer et al.
1996; Miller 1993; Taylor 1997; Van Dam
and de Vriend 1999; Wal and Pascal 1998).
It is this last question that was the subject of
the conference “Assessment of the Allergenic
Potential of Genetically Modified Foods”
held 10–12 December 2001 in Research
Triangle Park, North Carolina. Specifically,
how do we determine if a genetically modiﬁed
food is likely to be allergenic, given that peanut
and tree nut allergies alone are observed in
1.1% of the general U.S. population (Sicherer
et al. 1999)?
Overview of Allergic Reactions
to Foods
To address this question, it is ﬁrst necessary to
appreciate that a number of defined clinical
pathologic entities fall within the general pub-
lic perception of what defines food allergy
(Table 1) (Burks et al. 1988; Lake 1997; Min
and Metcalfe 1997; Smith and Munoz-
Furlong 1997; Sollid et al. 1989). Indeed, the
majority of reactions to foods are classic aller-
gic reactions (Jansen et al. 1994). These reac-
tions occur within minutes after ingestion of a
food and are manifested by urticaria, angio-
edema, rhinoconjunctivitis, nausea, vomiting,
diarrhea, and asthma. These reactions depend
on the synthesis of antigen-speciﬁc immuno-
globin E (IgE) by B cells in allergic individuals
with an inherited tendency for T-helper type 2
cell–like reactions, in which the T cells, when
activated, secrete cytokines such as interleukin
(IL)-4 and IL-5. This antigen-specific IgE
becomes ﬁxed on the surfaces of mast cells and
basophils within that sensitized individual.
Basophils circulate through the blood, and
mast cells are found with greater frequency on
surfaces of the body that interface the external
environment. When that individual is reex-
posed to the same antigen, it then cross-links
IgE on the surfaces of basophils and mast cells.
This leads to basophil and mast cell activation,
with the release of histamine, generation of
arachidonic metabolites, and the release and
generation of potent cytokines and chemo-
kines. These chemicals then interact with tar-
get-sensitive tissues and generate the allergic
response. For instance, if mast cells are acti-
vated within the gastrointestinal tract, this then
leads to nausea, vomiting, diarrhea, and the
ingress of antigen into the systemic circulation
where it may degranulate basophils within the
vascular compartment and mast cells within
target tissues. If such a reaction is severe, it
may result in profound hypotension and
be life threatening. This latter reaction is
called anaphylaxis.
However, not all reactions to foods on an
immunologic basis are IgE mediated. There
are non–IgE-mediated delayed reactions, par-
ticularly in infants and children, to such sub-
stances as milk protein. These reactions may
lead to vomiting, diarrhea, and failure to
thrive. Such reactions are sometimes termed
“food-induced enterocolitic syndromes”
(Lake 1997). The food components that
induce such reactions and the mechanisms
behind these reactions, which include
immune complex formation and activation of
lymphocytes, have yet to be fully defined.
Similarly, celiac disease (Sollid et al. 1989) is
a specific form of food allergy in which the
body reacts to components of specific cereal
grains, termed “glutens,” which leads to a
speciﬁc pathologic picture.
Efforts to date to address issues of aller-
genicity in engineered foods have concentrated
on IgE-mediated immediate reactions. Not
only are these reactions the most frequent, but
they are easily the most potentially life threat-
ening. Further, the specific antigens within
food that lead to such reactions and the effec-
tor cells and mediators involved have been rea-
sonably well characterized. The same cannot
be said for delayed reactions to food compo-
nents, seen primarily in infants and children.
Because gluten-sensitive entropy, or celiac dis-
ease, is speciﬁcally caused by glutens, any con-
sideration of allergenicity in a new food should
speciﬁcally address whether genes coding for
glutens have been transferred, and thus create
products that will be a problem for those with
celiac disease. This disease aside, however, the
majority of current efforts remain directed at
IgE-mediated allergic reactions.
The tools to aid in the diagnosis of food
allergy are limited (Bock et al. 1988; Jansen
et al. 1994; Pastorello et al. 1989). The most
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Genetically Modiﬁed Foods Mini-Monographcritical feature in the diagnosis of food allergy
is a carefully obtained clinical history of spe-
cific reactions to foods. What foods were
ingested, in what quantities, and in what con-
text? A careful history often reveals the food
that induced the allergic response. The his-
tory may be supplemented by careful use of
diet diaries and elimination diets (when safe
for a given individual). The suspicion that a
speciﬁc food induced an allergic response may
be reinforced by the demonstration of IgE
speciﬁc to the food in question. Testing usu-
ally takes one of several forms. The most
common test employed is the use of water-
soluble extracts applied to the skin. The skin
is then “tented” through the extract. If a per-
son is sensitive to allergens within the food in
question, a local, small allergic reaction con-
sisting of erythema, edema, and itching will
occur. Alternatively, blood obtained from
patients with suspected food allergies can be
subjected to examination using a radioallergo-
sorbent test (RAST) or enzyme-linked
immunosorbent assay (ELISA), which identi-
fies the presence of food-specific IgE within
serum. If history, cutaneous testing, and
RAST/ELISA do not demonstrate sensitivity,
it may on some occasions be necessary to
challenge the patient in a double-blind fash-
ion with suspected foods, masked either in
capsules or in another food (Jansen et al.
1994). This latter testing strategy should not
be used if the person is anaphylactically sensi-
tive to the suspected food. Further, if such
testing is performed, it should be done only
by a physician skilled in application of this
procedure, in the context of the equipment
available for intubation and the treatment of a
severe allergic reaction, and with the patient’s
informed consent.
Much of the need to address the safety of
modified foods is because currently there is
no available means to cure a given individual
of an immediate reaction to food. The strat-
egy for protection of a sensitive individual
involves instruction on dietary avoidance of
the foods in question. Patients also are
instructed on how to self-treat in the case that
inadvertent exposure occurs. Immediate
treatment for systemic reactions is the intra-
muscular injection of epinephrine followed by
acquisition of medical help. The reliance on
dietary avoidance by patients with food aller-
gies is the reason it is so important that new
allergenic foods not be created in the process
of the application of biotechnology.
Strategies to Determine If a
Modiﬁed Food Is Allergenic
It would seem, on ﬁrst pass, that the strategy
to prevent the creation of new allergenic foods
should be straightforward. The strategy that
has been proposed is simply to avoid transfer-
ring genes or genetic material that code for
known allergens or potential allergens, based
on their structure, and to screen products of
upregulated genes to determine if they code
for proteins with allergenic potential. The dif-
ﬁculty in this strategy is that the characteristics
of a protein with known allergenicity that
would distinguish this protein from a protein
unlikely to be allergenic are not known. This
in turn dictates that strategies to screen for
allergenicity must rely on what is known or
what can be determined about proteins coded
for by transferred genes or upregulated within
the target plant. To address these concerns, a
series of questions can be asked similar to
those in Table 2. Does the gene transferred
from a source material to the altered plant
code for a known allergen? Two approaches in
this regard have been widely applied. First, is
there sequence and structural similarity
between the transferred gene product and
known allergens? Second, does the transferred
gene code for a protein known to be aller-
genic? This is particularly relevant when the
gene is derived from a known allergenic
source. In this latter case, serum from individ-
uals sensitive to the source of the transferred
gene can be used to screen for the presence of
IgE reactive to the transferred protein as
expressed in the modiﬁed food. Clearly, sim-
ply examining sequence similarity does not
account for discontinuous and conformational
epitopes. However, with crystallization of
known allergens, it is possible to foresee a day
when such epitopes may be identiﬁed.
A more difficult question is whether the
transferred gene codes for a protein that may
be allergenic, when the source of the trans-
ferred protein is not known for its allergenicity.
Again, efforts can be made to determine
sequence similarity of the transferred gene to
known genes that code for allergens. Here,
resistance to degradation by proteases and acid
has been suggested as a relative screening
methodology (Astwood et al. 1996). Resistance
of a transferred protein to degradation is partly
based on the theory that resistance to degrada-
tion protects a protein from digestion and thus
allows for greater absorption of the protein.
Assessment of transferred proteins for potential
allergenicity has also generated interest in the
possible use of animal models to assess protein
allergenicity. This leads to another question.
Has the genetic manipulation of the modiﬁed
food upregulated endogenous substances that
may be allergenic? In the possible instance
where such upregulated proteins may not have
been identified, screening for allergenicity
again through the use of an animal model has
been attractive.
Decision Tree Approaches
The first organized attempt to synthesize a
plan in the form of a decision tree to address
issues of the allergenicity of engineered foods
was sponsored by the International Food
Biotechnology Counsel and the International
Life Sciences Allergy and Immunology
Institute. This decision tree and accompany-
ing articles were published in a supplement of
Critical Reviews in Food Science and
Nutrition (Metcalfe et al. 1996) after a num-
ber of other similar initiatives (FAO/WHO
1995, 1996; U.S. FDA 1992). This decision
tree envisioned two primary scenarios. The
first scenario is that the source of the trans-
ferred gene was allergenic. In this case, serum
from individuals allergic to the source of the
gene could be used to screen extracts of the
modified food to determine if an allergenic
protein had been transferred. The initial
screening is done using an in vitro measure-
ment of allergen-specific IgE, possibly fol-
lowed by skin testing of extracts of the
modified plant in individuals known to be
sensitive to the source material, and ﬁnally, by
the rare possibility of employing blinded food
challenge procedures in sensitive individuals.
In the second scenario, where the source of
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Table 1. Clinical patterns of immune-mediated
adverse reaction to foods. 
IgE mediated (immediate)
Urticaria/angioedema
Rhinoconjunctivitis, asthma
Oral allergy syndrome
Nausea, colic, vomiting, diarrhea
Anaphylaxis
Non-IgE mediated (delayed)
Food-induced enterocolitic syndromes
Celiac disease
Overlap
Atopic dermatitis
Allergic eosinophilic gastroenteritis
Controversial
Migraine headaches
Irritable bowel syndrome, etc.
Table 2. Examples of technical approaches to address questions concerning the possible allergenicity of
modiﬁed foods.
Sequence Reaction to Stability to Allergenicity in
Questions similarity speciﬁc IgE digestion an animal model
Does the gene transferred code X X X
for a known allergen? (Source is a
common allergenic food.)
Does the gene transferred code X X X
for a protein that may be allergenic?
Does the genetic manipulation lead to the  X
expression or upregulation of a new allergen?the gene is not known to be allergenic, the
decision tree recommends examining the
transferred gene for sequence similarity to
known allergens and for stability to digestion.
This decision tree has been widely discussed
and critiqued.
This initial decision tree was published in
1996 at a time when a number of modified
foods were in the process of being approved.
However, with the increasing use of genetically
modiﬁed plants in the late 1990s came a signif-
icant rise in public concern about the safety of
genetically modified foods (Enserink 1999;
Ferber 1999; Gaskell et al. 1999). Among the
many issues of public concern was the issue of
allergenicity. In part, public attention to these
issues was heightened by the circumstances sur-
rounding the approval of StarLink corn. In
1998, the U.S. Environmental Protection
Agency (U.S. EPA) decided to limit the use of
this corn for animal feed because the Cry9C
protein engineered into this corn to provide
pesticide resistance was resistant to degrada-
tion. Subsequently, in September 2000,
Cry9C DNA was detected in taco shells, and
the U.S. EPA and U.S. FDA became involved
in an assessment of whether the StarLink corn
was indeed allergenic (U.S. EPA 2001).
Over the same period, a number of criti-
cisms had been voiced about the 1996
International Life Sciences Institute/Inter-
national Food Biotechnology Consortium
(ILSI/IFBC) decision tree approach in assess-
ing allergenicity. In some cases, the use of
skin prick tests and double-blind placebo-
controlled food challenge were felt to be
inappropriate because of ethical concerns in
the use of normal volunteers for the purposes
of safety assessment. There was also signifi-
cant concern over exactly how many contigu-
ous amino acids deﬁned sequence similarity.
There was increasing evidence that stability to
digestion was a poor screen for allergenicity.
Further, there was no screen for cross-reacting
allergens. Finally, individuals interested in
animal models of allergenicity were making
the case that such models would help to
deﬁne allergenicity for safety assessment.
To address these concerns, the FAO/
WHO convened a special panel in 2001 to
update the ILSI/IFBC decision tree. This
revised decision tree most noticeably differs
from the ILSI/IFBC decision tree through the
insertion of screens for cross-reacting allergens
such as those that exist between ragweed and
melons, and through its advocacy of the use of
animal models in a relative scale of allergenic-
ity (FAO/WHO 2001). The FAO/WHO
panel also recommended that such approaches
to assess allergenicity must constantly take into
account new and evolving information on
parameters that deﬁne allergenicity and on the
evolving use of speciﬁc animal models. They
also noted that use of human in vivo methods
to evaluate the allergenicity of food derived
from biotechnology in many circumstances
raised ethical issues, and their use would have
to be considered on a case-by-case basis and as
relates to the value of premarketing evaluation.
This was particularly important in the assess-
ment of foods claimed to be hypoallergenic
through the downregulation of genes that
code for known allergens.
Questions in Risk Assessment
If it were possible to list with certainty the
characteristics that allow a speciﬁc protein to
induce speciﬁc IgE in a susceptible individual,
there would have been no need for this con-
ference. The reality is, however, that we have
only imperfect and relative measures of aller-
genic potential at present (Table 2). Given
the current situation, what issues now need to
be addressed?
It may be argued that the ﬁrst set of issues
centers around the understanding of patho-
physiologic mechanisms of allergenicity. How
do we define susceptible populations? What
are the thresholds for sensitization? What are
the thresholds for elicitation of a reaction?
What do we know about dose–response
relationships between the amount of food
ingested and the final reaction? And finally,
what available biomarkers are there of
exposure and effect?
A second series of issues related to the
mechanisms of allergenicity is directed to
allergenic structure. What are the molecular
determinants of allergenicity? Is there a rela-
tionship between allergenicity and function?
And finally, is it possible to use animal
models to predict allergenicity?
Assuming that any effort to identify
genetically modified foods of potential aller-
genicity using current technology will not be
perfect, what then is the role of postmarket
surveillance? Is it practical to label genetically
modified organism (GMO) foods, consider-
ing that many of these foods will be
processed? And what about the issue of post-
marketing surveillance in situations where
foods are sold in restaurants and through
street vendors and in other situations where
monitoring of labeling becomes difﬁcult?
It was thus the charge of this meeting to
examine the issues surrounding the potential
allergenicity of GMO foods. What is the true
value and role of an assessment of new proteins
in GMO foods in terms of similarity to known
allergens? How many contiguous amino acids
deﬁne similarity? What are the limitations and
strengths of tests to examine stability of pro-
teins? Is there sufficient information to sup-
port the use of animal models in evaluating
allergens to allow their rational use in safety
assessment? To what degree can safety assess-
ment rely on testing of GMO foods using sera
from those known to be allergic to source
materials, pollens, and other substances in the
environment? In the end, decisions made as to
how to apply existing knowledge and databases
in the assessment of GMO foods for potential
allergenicity will be only as successful as they
are creditable to research scientists, industry,
and to the public at large.
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